A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.
Also called NCT03398005
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 256 participants
- Sponsor
- Registry
-
NCT03398005
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03398005. Randomized; double masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2019-07-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
- Acronym
- TRILOGY 1
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- CaPre
- Intervention (Drug)
- Placebo
- Lead sponsor
- Grace Therapeutics Inc.
Record details
- Record id
cardio:ct-nct03398005- Content hash
c60aaf0c6f67081270396250d70cb29e0a6e015a0ef5f6dfbbba929f25520bf1